All In Biotech

Drug Trial Radar · NCT00360243

6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA

Last checked: Nov 20, 2026Latest source record: Jun 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,385 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,385

Actual

Start

Jul 2006

Primary completion

Apr 2008

Study completion Apr 2008

Sponsor

Lead sponsor
Sprout Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Aug 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meet standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.

Conditions

  • Sexual Dysfunctions, Psychological

Interventions

  • flibanserinDrug

    Experimental: flibanserin 25 mg b.i.d

  • flibanserinDrug

    Experimental: flibanserin 50mg qhs

  • flibanserinDrug

    Experimental: flibanserin 50mg b.i.d.

  • placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline to 24 Weeks in the Frequency of Satisfying Sexual Events as Measured by the eDiary.Time frame: 24 weeks
  2. Change From Baseline to 24 Weeks in Responses to the eDiary Daily Desire Question.Time frame: baseline to 24 weeks

Locations

81 sites in 1 country. Site status is shown where the registry gives one.

  • 511.70.01068 Boehringer Ingelheim Investigational Site

    Huntsville, Alabama

  • 511.70.01040 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 511.70.01041 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 511.70.01003 Boehringer Ingelheim Investigational Site

    Jonesboro, Arkansas

  • 511.70.01070 Boehringer Ingelheim Investigational Site

    Carmichael, California

  • 511.70.01026 Boehringer Ingelheim Investigational Site

    Redding, California

  • 511.70.01015 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 511.70.01014 Boehringer Ingelheim Investigational Site

    Stanford, California

  • 511.70.01017 Boehringer Ingelheim Investigational Site

    Tarzana, California

  • 511.70.01072 Boehringer Ingelheim Investigational Site

    Torrance, California

  • 511.70.01078 Boehringer Ingelheim Investigational Site

    Vista, California

  • 511.70.01066 Boehringer Ingelheim Investigational Site

    Walnut Creek, California

  • 511.70.01064 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 511.70.01001 Boehringer Ingelheim Investigational Site

    Wheat Ridge, Colorado

  • 511.70.01050 Boehringer Ingelheim Investigational Site

    Farmington, Connecticut

  • 511.70.01006 Boehringer Ingelheim Investigational Site

    Hartford, Connecticut

  • 511.70.01055 Boehringer Ingelheim Investigational Site

    New London, Connecticut

  • 511.70.01024 Boehringer Ingelheim Investigational Site

    Aventura, Florida

  • 511.70.01056 Boehringer Ingelheim Investigational Site

    Daytona Beach, Florida

  • 511.70.01090 Boehringer Ingelheim Investigational Site

    Fort Lauderdale, Florida

  • 511.70.01027 Boehringer Ingelheim Investigational Site

    Gainesville, Florida

  • 511.70.01062 Boehringer Ingelheim Investigational Site

    New Port Richey, Florida

  • 511.70.01043 Boehringer Ingelheim Investigational Site

    Orlando, Florida

  • 511.70.01084 Boehringer Ingelheim Investigational Site

    Pembroke Pines, Florida

  • 511.70.01048 Boehringer Ingelheim Investigational Site

    St. Petersburg, Florida

  • 511.70.01042 Boehringer Ingelheim Investigational Site

    Stuart, Florida

  • 511.70.01063 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 511.70.01085 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 511.70.01086 Boehringer Ingelheim Investigational Site

    West Palm Beach, Florida

  • 511.70.01022 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 511.70.01057 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 511.70.01087 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 511.70.01052 Boehringer Ingelheim Investigational Site

    Roswell, Georgia

  • 511.70.01060 Boehringer Ingelheim Investigational Site

    Champaign, Illinois

  • 511.70.01058 Boehringer Ingelheim Investigational Site

    Chicago, Illinois

  • 511.70.01032 Boehringer Ingelheim Investigational Site

    Indianapolis, Indiana

  • 511.70.01018 Boehringer Ingelheim Investigational Site

    Lexington, Kentucky

  • 511.70.01007 Boehringer Ingelheim Investigational Site

    Baton Rouge, Louisiana

  • 511.70.01047 Boehringer Ingelheim Investigational Site

    New Orleans, Louisiana

  • 511.70.01079 Boehringer Ingelheim Investigational Site

    New Orleans, Louisiana

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.